Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Patients at risk for recurrence or death at successive follow-up times

From: Progranulin (GP88) tumor tissue expression is associated with increased risk of recurrence in breast cancer patients diagnosed with estrogen receptor positive invasive ductal carcinoma

Patients at risk for recurrence
years 0 1 2 3 4 5 6 7 8 9 10 11 12
GP88 < 3+ 217 213 199 187 170 142 111 88 62 38 29 21 11
GP88 = 3+ 47 44 41 33 25 19 12 8 4 2 1 0 0
Patients at risk for death
years 0 1 2 3 4 5 6 7 8 9 10 11 12
GP88 < 3+ 217 214 201 192 178 148 120 9 66 42 30 22 11
GP88 = 3+ 47 46 44 37 31 25 18 13 6 2 1 0 0
  1. The data show the number of patients at risk for recurrence or death at 12-month intervals out to 12 years following initial diagnosis in the two GP88 groups (GP88 < 3+ and GP88+3+) in the validation study. The maximum follow-up was 122 months in the GP88 = 3+ group and 205 months in the GP88 < 3+ group,